LAG3 and metastatic melanoma: Given the RELATIVITY-047 clinical trial findings, the FDA recently approved using relatlimab, a medication targeting lymphocyte-activation gene 3 (LAG-3), with nivolumab to treat unresectable or metastatic melanoma.